Catalina_Barrett
Posted - 1 day ago
$CNTX $SGMT $IPHA LFG, expected this to move higher. Also, your thoughts on MYNZ? Who's behind the 30M share offering deal? 👀 And how could the Thermo Fisher (TMO) partnership ($210B market cap) reflect this stock movement and PR buzz everywhere on socials?
neo55
Posted - 2 days ago
$IPHA Jonathan Dickinson appointed Chief Executive Officer and Chairman of the Executive Board Encouraging initial FDA feedback received on lacutamab regulatory pathway Lacutamab health-related quality of life and translational data to be presented at the upcoming ASH Annual Meeting IPH4502, a Nectin-4 ADC received FDA clearance of the IND to be developed in solid tumors Preclinical data for proprietary tetra-specific NK cell engager IPH6501 and novel ADC IPH4502 presented at SITC Cash position of €96.4 million1 as of September 30, 2024, anticipated cash runway to end of 2025
First_Class_Seaman
Posted - 4 days ago
$ZONE float is lock and shorts are stuck.
$SEAT head to 4+
$IPHA WW. Added some here at this level
Deni_Cain
Posted - 6 days ago
$IPHA $PBYI MYNZ Wow, this is insane news! Don't miss out. The train is leaving the station. Add it to your watchlist to see what happens next. 😏
Billianas
Posted - 10/28/24
$IPHA let it drop to 1$ range. Would be definitely a buy then.
neo55
Posted - 1 month ago
$IPHA better do something with this company years of lackluster news and innovation
themacromindset
Posted - 1 month ago
$IPHA Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
neo55
Posted - 09/23/24
$IPHA great news no movement ?
DonCorleone77
Posted - 09/23/24
$IPHA Innate Pharma announces FDA clearance of IPH4502 IND Innate Pharma announced that the FDA has cleared its investigational new drug, or IND, application to initiate a Phase 1 clinical study of IPH4502, its novel and differentiated topoisomerase I inhibitor antibody drug conjugate, or ADC, targeting Nectin-4 in solid tumors. Innate expects to initiate the Phase 1 study in the coming months. The Phase 1, open-label, multi-center study, includes a Part 1 Dose Escalation and a Part 2 Dose Optimization, and will assess the safety, tolerability, and preliminary efficacy of IPH4502 as a single agent in advanced solid tumors known to express Nectin-4, including but not limited to urothelial carcinoma, non-small cell lung, breast, ovarian, gastric and colorectal cancers.
Dantodd2k1
Posted - 09/23/24
$IPHA
Dantodd2k1
Posted - 09/23/24
$IPHA 👀👀👀
Stock_Titan
Posted - 09/23/24
$IPHA Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
https://www.stocktitan.net/news/IPHA/innate-pharma-announces-fda-clearance-of-the-ind-for-iph4502-a-iereu8h7ka9d.html
Stock_Titan
Posted - 2 months ago
$IPHA Innate Pharma Reports First Half 2024 Business Update and Financial Results
https://www.stocktitan.net/news/IPHA/innate-pharma-reports-first-half-2024-business-update-and-financial-yl6xl6z2bmnk.html
DonCorleone77
Posted - 2 months ago
$IPHA $AZN Innate Pharma reports AstraZeneca presentation of results from NeoCOAST-2 study Innate Pharma (IPHA) announced that AstraZeneca (AZN) presented interim results from the randomized NeoCOAST-2 Phase 2 platform study during the 2024 World Conference on Lung Cancer on September 8. The NeoCOAST-2 platform study is intended to assess the safety and efficacy of neoadjuvant durvalumab alone or combined with novel agents and chemotherapy in resectable, early-stage non-small cell lung cancer, or NSCLC, followed by adjuvant treatment with durvalumab with or without the novel agents. The preliminary data of three arms were presented at WCLC, namely: Arm 1: oleclumab in combination with durvalumab and platinum doublet chemotherapy in the neoadjuvant setting and durvalumab plus oleclumab in the adjuvant setting; Arm 2: monalizumab in combination with durvalumab and platinum doublet chemotherapy in the neoadjuvant setting and durvalumab plus monalizumab in the adjuvant setting and; Arm 4: datopotamab deruxtecan in combination with durvalumab and single agent platinum chemotherapy in the neoadjuvant setting, and durvalumab alone in the adjuvant setting. In this preliminary analysis on the first 60 of 72 patients randomized to Arm 2, monalizumab added to durvalumab plus platinum-based chemotherapy doublet induced a pathological complete response rate of 26.7% and a major pathological response rate of 53.3% which are numerically higher than the durvalumab plus platinum doublet approved regimen. Treatment in Arm 2 showed manageable safety profile and no impact on surgical rate.
Stock_Titan
Posted - 2 months ago
$IPHA $AZN Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
https://www.stocktitan.net/news/IPHA/innate-pharma-sa-monalizumab-data-from-neo-coast-2-phase-2-study-in-87gmhcfhkrzp.html
Stock_Titan
Posted - 2 months ago
$IPHA Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
https://www.stocktitan.net/news/IPHA/innate-pharma-announces-conference-call-and-webcast-for-first-half-9nd8exsre9i2.html
Stock_Titan
Posted - 2 months ago
$IPHA Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
https://www.stocktitan.net/news/IPHA/innate-pharma-announces-its-participation-in-the-h-c-wainwright-26th-lwbi253x9mur.html
SeekingOctane
Posted - 08/29/24
$VINC Huge move coming on this sleeping adc giant Vincerx. CEO ran Acerta sold for $7 billion and CMO of Pharmacyclics sold for $21 billion. VIP236 same warhead as Trodelvy which Gilead bought for $21 billion.
Management just repriced options to capture upside back to $5
$LVTX $IPHA $NUVB
Hmehtakp
Posted - 3 months ago
$IPHA LOL 😂
Hmehtakp
Posted - 3 months ago
$IPHA no chatter …..
neo55
Posted - 06/28/24
$IPHA this company stock performance is worst than Joe Biden debate performance 🎭
DonCorleone77
Posted - 5 months ago
$IPHA $SNY Innate Pharma announces updated results from SAR443579/IPH6101 Innate Pharma (IPHA) announced that updated efficacy and safety results from the dose-escalation part of the Phase 1/2 study with SAR443579/IPH6101, an investigational CD123 targeting NKp46/CD16-based Natural Killer Cell Engager, or NKCE, from a joint research collaboration between Innate Pharma and Sanofi (SNY) and Anket platform lead asset, were shared in an oral presentation at the European Hematology Association 2024 Congress in Madrid, Spain on Sunday. The study, led by Sanofi, tests SAR'579 as a monotherapy for the treatment of blood cancers with high unmet needs, including relapsed or refractory acute myeloid leukemia, B-cell acute lymphoblastic leukemia and high-risk myelodysplasia. SAR'579 has FDA Fast Track Designation for the treatment of acute myeloid leukemia. Fifty-nine patients across 11 dose levels were treated. Patients had received a median of 2 prior lines of treatment. A maximum response rate was observed at a final target dose of 1 mg/kg every week with 5 AML patients achieving a CR. The median treatment duration was 7.9 weeks, with durable CR observed in 3 patients with 2 remaining on maintenance therapy as of the data cutoff. SAR'579 was well tolerated up to doses of 6 mg/kg every week. These data will form the basis for selection of recommended doses for development in the Phase 2 portion of the trial.
Stock_Titan
Posted - 5 months ago
$IPHA Innate Pharma Shares Updated Results From the Sanofi Developed Blood Cancer Phase 1/2 SAR443579/IPH6101 Trial
https://www.stocktitan.net/news/IPHA/innate-pharma-shares-updated-results-from-the-sanofi-developed-blood-xqfyu96nyrtd.html
neo55
Posted - 5 months ago
$IPHA this company lost 1/3 $80 million dollar value with less than 100 k share traded in a few weeks with no apparent catalyst drip drip drip everyday
BioTuesdays
Posted - 5 months ago
Innate Pharma S.A. presented positive results from its Phase 2 TELLOMAK study with lacutamab in mycosis fungoides at the ASCO 2024 Annual Meeting in Chicago $IPH $IPHA https://biotuesdays.com/2024/06/05/innate-pharma-announces-positive-outcomes-from-tellomak-phase-2-study/
DonCorleone77
Posted - 5 months ago
$IPHA Innate Pharma announces results from TELLOMAK study Innate Pharma announced results from the Phase 2 TELLOMAK study with lacutamab in mycosis fungoides, or MF. The results were presented at the ASCO 2024 annual meeting, in Chicago, Illinois. As of October 13, 2023, data cutoff, MF patients received a median of four prior systemic therapies and had a median follow-up of 11.8 months. The data demonstrate that treatment with lacutamab resulted in meaningful antitumor activity, regardless of the KIR3DL2 baseline expression, and an overall favorable safety profile. The global objective response rate, or ORR, was 16.8% and 22.4%, including 2 complete responses and 16 partial responses. In patients expressing a baseline KIR3DL2 of 1%, the ORR was 20.8% and 29.2%. Median progression-free survival was 10.2 months for all MF patients and 12 months in the KIR3DL2 1% group. Time to response was one month.
Stock_Titan
Posted - 5 months ago
$IPHA Innate Pharma Presents Positive Results From TELLOMAK Phase 2 Study With Lacutamab in Mycosis Fungoides
https://www.stocktitan.net/news/IPHA/innate-pharma-presents-positive-results-from-tellomak-phase-2-study-z01q10gy7qpp.html
dhovekamp42
Posted - 05/31/24
$AFMD $IPHA future NK-cell therapies - safe, effective and durable https://x.com/HindRafei/status/1796226054098477283
